Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
Here's Why Puma Biotechnology Fell as Much as 40.7% Today | The Motley Fool
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut - August 6, 2021 - Zacks.com
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut | Nasdaq
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Here's Why Puma Biotechnology Tumbled Today | The Motley Fool
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
